Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 9/20 | 0.40 |
| ▸ | RARA | P10276 | 8/20 | 0.40 |
| ▸ | RARG | P13631 | 8/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292938 | 0.81 | NPC1 (0.45) | NPC1MAPTRAB9APGRHSD17B1 | |
| SCHEMBL3903931 | 0.80 | RARB (0.60) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6234465 | 0.79 | RARB (0.58) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL5707339 | 0.77 | RARB (0.59) | NPC1MAPTRAB9APGRRARB | |
| SCHEMBL7642223 | 0.76 | RARA (0.61) | RARBRARARARG | |
| SCHEMBL6292978 | 0.76 | NPC1 (0.38) | NPC1MAPTRAB9APGRHSD17B1 | |
| SCHEMBL8125507 | 0.76 | ALDH1A1 (0.42) | NPC1MAPTRAB9APGRHSD17B1 | |
| SCHEMBL6086265 | 0.76 | RXRA (0.51) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL8771833 | 0.75 | RARB (0.52) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL8125508 | 0.75 | KMT2A (0.40) | NPC1MAPTRAB9APGRHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | NPC1 3809/4885MAPT 4165/4885RAB9A 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.